Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
Company Details
- Founded
- 2009
- Address
- Wilhelminasingel 14, Nijmegen,gelderland 6524,netherlands
- Phone
- +31 24 300 01 00
- in****@****kos.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- xenikos.com
- Keywords
- Biotechnology, Immunotherapy, Medicine, Drug development, Clinical development, Biopharmacy.
- HQ
- Nijmegen, Gelderland
Xenikos B.v. Questions
Xenikos B.V.'s helpline number is +31 24 300 01 00
Xenikos B.V.'s website is xenikos.com
Xenikos B.V.'s LinkedIn profile is https://nl.linkedin.com/company/xenikos-b-v
Xenikos B.V.'s industry is
Biotechnology Research
Xenikos B.V.'s top competitors are
Lava Therapeutics N.v.,
Cimcure B.v.,
Khondrion,
Nc Biomatrix B.v.,
Vaxxinova,
Artemis Bioservices,
Byondis,
Pedmed-Nl,
Synthon,
Protinhi Therapeutics.
Xenikos B.V.'s support email address is info@xenikos.com
Xenikos B.V.'s categories are Biotechnology Research
Xenikos B.V.'s founding year is 2009
